Uploaded March 2026 | Updated September 2026, 3 weeks ago
Is your GLP-1 medication doing more than managing your weight or blood sugar? A landmark new study published in the British Medical Journal says it might — and the findings are hard to ignore.
A team of researchers from the VA Saint Louis Health Care System just released the most comprehensive study ever conducted on GLP-1 receptor agonists and substance use disorders. Using data from 606,434 US veterans with type 2 diabetes and nearly 1.6 million person-years of follow-up, they found that people on GLP-1 medications had significantly lower risks of developing alcohol, opioid, cocaine, nicotine, and cannabis use disorders — and dramatically better outcomes if they already had one.
In this episode of The Weekly Shot, RMZ breaks down exactly what the study found, how it was designed, why the methodology matters, and what it means for the GLP-1 community.
What we cover:
Why this study is different from everything that came before it
The two-part design: prevention AND treatment of substance use disorders
Key results: opioid risk down 25%, SUD-related mortality cut in half
The brain science behind why GLP-1s may quiet more than just food noise
What this study can and cannot tell us — the honest caveats
What it means for people already on Zepbound, Wegovy, or Mounjaro
📄 Study: Cai M, Choi T, Xie Y, Al-Aly Z. "Glucagon-like peptide-1 receptor agonists and risk of substance use disorders among US veterans with type 2 diabetes: cohort study." BMJ 2026;392:bmj-2025-086886.
🔗 bmj.com/content/392/bmj-2025-086886
Social Links
tiktok.com/@roundmoundofzepbound
instagram.com/roundmoundofzepbound
DISCLAIMER: No information provided here is to be construed as medical advice. Always consult with a licensed medical provider for medical advice.
#glp1#zepbound #mounjaro #weightloss #weightlossjourney #glp #tirzepatide #semaglutide #wegovy #ozempic #menshealth #beforeandafter #beforeandafterweightloss
Is your GLP-1 medication doing more than managing your weight or blood sugar? A landmark new study published in the British Medical Journal says it might — and the findings are hard to ignore.
A team of researchers from the VA Saint Louis Health Care System just released the most comprehensive study ever conducted on GLP-1 receptor agonists and substance use disorders. Using data from 606,434 US veterans with type 2 diabetes and nearly 1.6 million person-years of follow-up, they found that people on GLP-1 medications had significantly lower risks of developing alcohol, opioid, cocaine, nicotine, and cannabis use disorders — and dramatically better outcomes if they already had one.
In this episode of The Weekly Shot, RMZ breaks down exactly what the study found, how it was designed, why the methodology matters, and what it means for the GLP-1 community.
What we cover:
Why this study is different from everything that came before it
The two-part design: prevention AND treatment of substance use disorders
Key results: opioid risk down 25%, SUD-related mortality cut in half
The brain science behind why GLP-1s may quiet more than just food noise
What this study can and cannot tell us — the honest caveats
What it means for people already on Zepbound, Wegovy, or Mounjaro
📄 Study: Cai M, Choi T, Xie Y, Al-Aly Z. "Glucagon-like peptide-1 receptor agonists and risk of substance use disorders among US veterans with type 2 diabetes: cohort study." BMJ 2026;392:bmj-2025-086886.
🔗 bmj.com/content/392/bmj-2025-086886
Social Links
tiktok.com/@roundmoundofzepbound
instagram.com/roundmoundofzepbound
DISCLAIMER: No information provided here is to be construed as medical advice. Always consult with a licensed medical provider for medical advice.
#glp1#zepbound #mounjaro #weightloss #weightlossjourney #glp #tirzepatide #semaglutide #wegovy #ozempic #menshealth #beforeandafter #beforeandafterweightloss
